,77,78 Combination strategies using CD137 inhibitors with other immune checkpoint inhibitors may improve therapeutic outcomes through enhanced T-cell infiltration into tumor tissues and reduced inflammation in immune-mediated eye diseases.77 The gene discussed is TNFRSF9; the disease is neoplasm.